![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1776193
¼¼°èÀÇ S»ó °áÀå°æ ½ÃÀå : ½ÃÀå ÀλçÀÌÆ®, °æÀï ±¸µµ, ½ÃÀå ¿¹Ãø(2032³â)Sigmoidoscopes - Market Insights, Competitive Landscape, and Market Forecast - 2032 |
S»ó °áÀå°æ ½ÃÀåÀº ´ëÀå¾Ï, ¿°Áõ¼º ÀåÁúȯ(IBD), °Ô½Ç¿°, Æú¸³°ú °°Àº ¸¸¼ºÁúȯÀÇ Áõ°¡, °í·É Àα¸ Áõ°¡, À§Àå ÁúȯÀÇ Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÃÖ¼Òħ½ÀÀû ½Ã¼ú·ÎÀÇ Àüȯ µîÀ¸·Î ÀÎÇØ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áõ°¡, ÃÖ¼Òħ½ÀÀû ½Ã¼ú·ÎÀÇ Àüȯ Áõ°¡ µîÀ¸·Î Å©°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, 2025³âºÎÅÍ 2032³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È S»ó °áÀå°æ ¼ö¿ä¸¦ È®´ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
S»ó °áÀå°æ ½ÃÀå ¿ªÇÐ:
Global Cancer Observatory(2024)¿¡ µû¸£¸é ´ëÀå¾ÏÀº ¾Æ½Ã¾Æ¿¡¼ 50.2%, À¯·´¿¡¼ 27.9%, ¾ÆÇÁ¸®Ä«¿¡¼ 3.7%¸¦ Â÷ÁöÇÕ´Ï´Ù. ¶ÇÇÑ, 2022³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î ¾à 139¸¸ ¸íÀÇ ´ëÀå¾Ï ȯÀÚ°¡ ¹ß»ýÇϰí, 2045³â¿¡´Â 329¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü ¼¼°èÀûÀÎ ºÎ´ãÀÇ Áõ°¡´Â Á¶±â ¹ß°ß°ú Áø´ÜÀÇ Çʿ伺ÀÌ °è¼Ó Áõ°¡Çϰí ÀÖ´Â °¡¿îµ¥ S»ó °áÀå°æÀÇ ¼ö¿ä¸¦ Å©°Ô Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.
S»ó °áÀå°æÀº ´ëÀå¾ÏÀÇ Á¶±â ¹ß°ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, S»ó °áÀå°æÀ» ÅëÇØ ÀÇ»ç´Â ¾Ï°ú Æú¸³ÀÌ Àß ¹ß»ýÇÏ´Â Á÷Àå°ú SÀÚ °áÀåÀ» Á÷Á¢ º¼ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, S»ó °áÀå°æÀº ¿¹¹æ ÀÇ·á ¹× ÀÏ»óÀûÀÎ Áø´Ü ÇÁ·ÎÅäÄÝÀÇ Áß¿äÇÑ ±¸¼º¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ, World Gastroenterology Organization(2024)Àº ¿©¼ºÀÇ 49%, ³²¼ºÀÇ 36.6%°¡ Àû¾îµµ ÇÑ °¡Áö ÀÌ»óÀÇ ±â´É¼º À§ÀåÀå¾Ö(FGID) ±âÁØÀ» ÃæÁ·ÇÑ´Ù°í º¸°íÇß½À´Ï´Ù. °¡Àå ÈçÇÑ ÁúȯÀº ±â´É¼º º¯ºñ(11.7%), ±â´É¼º ¼ÒȺҷ®(7.2%), Á÷ÀåÅë(5.9%), ±â´É¼º ¼³»ç(4.7%), °ú¹Î¼º ´ëÀåÁõÈıº(IBS)(4.1%)À̾ú½À´Ï´Ù. À̵é ÁúȯÀÇ ´ëºÎºÐÀº Á¤È®ÇÑ Áø´Ü°ú Ä¡·á °èȹÀ» À§ÇØ Á÷Àå°ú S»ó°áÀåÀ» Á÷Á¢ °Ë»çÇØ¾ß Çϱ⠶§¹®¿¡ º´¿ø, ÀÇ¿ø, ¼Òȱ⼾ÅÍ¿¡¼ S»ó°áÀå°æ °Ë»çÀÇ µµÀÔÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î ¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÊ¿¡ µû¶ó ÀÇ·á ½Ã½ºÅÛÀº ÷´Ü Áø´Ü µµ±¸¿Í ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. Á¶±â ¹ß°ß°ú ¿¹¹æ ÀÇ·á°¡ ´õ¿í °Á¶µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù Olympus CorporationÀº Å¿õ¸ÞµðÄ®(Taewoong Medical Co, Ltd.)À» 3¾ï 7,000¸¸ ´Þ·¯¿¡ ÀμöÇß½À´Ï´Ù. ÀÌ Àü·«Àû Àμö´Â ¿Ã¸²Çª½ºÀÇ ¼Òȱâ Ä¡·á Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ°í ¼Òȱâ ÁúȯÀÇ Áø´Ü ¹× Ä¡·á Àåºñ ¿ª·®À» °ÈÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é(2024³â) 2050³â±îÁö Àü ¼¼°è ³ëÀÎ Àα¸ÀÇ ¾à 80%°¡ ÁßÀú¼Òµæ ±¹°¡¿¡ °ÅÁÖÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³ëÀεéÀº Á¶±â Áø´ÜÀÌ ÇÊ¿äÇÑ ¼Òȱâ Áúȯ¿¡ °É¸®±â ½±±â ¶§¹®¿¡ S»ó °áÀå°æ°ú °°ÀÌ Á¢±Ù¼ºÀÌ ÁÁÀº Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
µû¶ó¼, ´ëÀå¾Ï ¹ßº´·ü Áõ°¡, FGIDs ¹ßº´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÀÇ·á ¹ßÀüÀÇ Á¶ÇÕÀº 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È S»ó °áÀå°æ ½ÃÀåÀÇ °·ÂÇÑ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±×·¯³ª ´ëü Áø´Ü ¹æ¹ýÀÇ °¡¿ë¼º, S»ó °áÀå°æ °Ë»ç¿¡ µû¸¥ ÇÕº´Áõ ¹× °¨¿°ÀÇ ÀáÀçÀû À§Çè, ȯÀÚÀÇ ºÒÆíÇÔ µîÀ¸·Î ÀÎÇØ ÀÏÁ¤ÇÑ ÇѰ迡 Á÷¸éÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â º¸±Þ¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
S»ó °áÀå°æ ½ÃÀå ºÎ¹® ºÐ¼®:
Á¦Ç° À¯Çü(°æÁú, ¿¬Áú), »ç¿ë¼º(ÀÏȸ¿ë, Àç»ç¿ë), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø/Ŭ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ), Áö¿ª(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ±âŸ) º° S»ó °áÀå°æ ½ÃÀå ºÐ¼®
S»ó °áÀå°æ Á¦Ç° À¯Çüº°·Î´Â ¼ÒÇÁÆ® Ä«Å×°í¸®°¡ 2024³â¿¡ °¡Àå Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â °æ¼º ¸ðµ¨¿¡ ºñÇØ ¸¹Àº ÀåÁ¡ÀÌ Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿¬¼º S»ó °áÀå°æÀÇ Ã¤Åà Ȯ´ë´Â Àüü S»ó °áÀå°æ ½ÃÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖÀ¸¸ç, ±× ÁÖ¿ä ÀÌÀ¯´Â ÀÓ»óÀû À¯¿ë¼º Çâ»ó, ȯÀÚ ÆíÀǼº, ÁøÈÇÏ´Â ±â¼ú¿¡ ±âÀÎÇÕ´Ï´Ù. °æ¼º S»ó °áÀå°æ°ú ´Þ¸® ¿¬¼º S»ó °áÀå°æÀº SÀÚ °áÀåÀ» ´õ ±íÀÌ °üÂûÇÒ ¼ö ÀÖ°í Á¶ÀÛ¼ºÀÌ ÁÁ¾Æ Àǻ簡 ´õ ³ôÀº Á¤È®µµ·Î ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ÀÌµé ±â±â´Â ÅëÁõÀÌ Àû°í ÁøÁ¤Á¦°¡ ÇÊ¿ä ¾ø´Â °æ¿ì°¡ ¸¹À¸¸ç, ¿Ü·¡¿¡¼ ½Ã¼úÀÌ °¡´ÉÇϱ⠶§¹®¿¡ º¸´Ù Á¢±Ù¼ºÀÌ ³ô°í ºñ¿ë È¿À²ÀûÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ³»½Ã°æ ºÐ¾ßÀÇ ¼¼°è ¸®´õÀÎ ¿Ã¸²Çª½º(Olympus Corporation)´Â °íÈÁú ¿µ»ó°ú Á¡¸· °¡½Ã¼ºÀ» °ÈÇÏ´Â NBI(Narrow Band Imaging) ±â¼ú·Î ¾Ë·ÁÁø EVIS EXERA III Ç÷§ÆûÀÇ ÀϺηΠ÷´Ü ¿¬¼º S»ó °áÀå°æÀ» Á¦°øÇÕ´Ï´Ù. ÆæÅ¹½º¸ÞµðÄ®Àº ÀÎü°øÇÐÀû µðÀÚÀΰú HD+ °¡½Ã¼ºÀ» Ư¡À¸·Î ÇÏ´Â EC-3490LK¿Í °°Àº ¿¬¼º ºñµð¿À S»ó °áÀå°æÀ» »ý»êÇϰí ÀÖÀ¸¸ç, ¼Òȱ⠺´µ¿ ¹× Ŭ¸®´Ð¿¡¼ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ƯÈ÷ ÀÇ·á ½Ã½ºÅÛÀÌ ´ëÀå¾Ï ¿¹¹æ ÀǷḦ Áß½ÃÇÏ´Â °¡¿îµ¥, ¿¬¼º S»ó °áÀå°æ °Ë»ç´Â Á¤±âÀûÀÎ ´ëÀå °ËÁø °Ë»ç¿¡¼ ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡¿À°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ, Ambu A/S¿Í °°Àº ±â¾÷µéÀº Ambu(R) aScope Gastro¿Í °°Àº ÀÏȸ¿ë ¿¬¼º S»ó °áÀå°æÀ» Ãâ½ÃÇÏ¿© ÆíÀǼº°ú ¹«±Õ¼ºÀ» Á¦°øÇÏ¸é¼ °¨¿° °ü¸® ¹®Á¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. ¿µ±¹ÀÇ NHS Bowel Scope Screening°ú °°Àº ±¹°¡ ¾Ï °ËÁø ÇÁ·Î±×·¥¿¡ ¿¬¼º S»ó °áÀå°æ °Ë»ç°¡ ÅëÇÕµÇ¸é¼ ÀÓ»ó µµÀÔÀÌ ´õ¿í °¡¼Óȵǰí ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¿¬¼º S»ó °áÀå°æ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö¸é¼ ±¤ÇÐ Åõ¸í¼º, µðÁöÅÐ ¿µ»ó ó¸®, ÀÏȸ¿ë Æ÷¸ËÀÇ °³¼±°ú ÇÔ²² S»ó °áÀå°æ ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
ºÏ¹Ì°¡ Àüü S»ó °áÀå°æ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù:
¸ðµç Áö¿ª Áß ºÏ¹Ì´Â 2024³â S»ó °áÀå°æ ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ±â¼ú ¹ßÀü, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ÁÖ¿ä ±â¾÷ÀÇ ´ë±Ô¸ð ½ÃÀå ÀÔÁö, ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ, 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È S»ó °áÀå°æ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â Çõ½ÅÀûÀÎ Á¦Ç° °³¹ß·Î °ÈµÈ ´ëÀå¾Ï ȯÀÚ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.
±¹Á¦¾Ï¿¬±¸¼ÒÀÇ µ¥ÀÌÅÍ(2024³â)¿¡ µû¸£¸é, ºÏ¹ÌÀÇ ½Å±Ô ´ëÀå¾Ï ȯÀÚ ¼ö´Â ¾à 18¸¸ 4,000¸íÀ̸ç, ÀÌ ¼öÄ¡´Â 2050³â±îÁö 25¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ëÀå¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â ¹ß°ß°ú È¿°úÀûÀÎ °ËÁø ¹æ¹ýÀÇ Çʿ伺ÀÌ ´õ¿í Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. Á÷Àå°ú S»ó °áÀåÀ» °Ë»çÇÏ´Â Áß¿äÇÑ Áø´Ü¹ýÀÎ S»ó °áÀå°æ °Ë»ç´Â ´ëÀåÁ÷Àå ÀÌ»ó ¹ß°ß°ú ¸ð´ÏÅ͸µ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ´ëÀå¾ÏÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó S»ó °áÀå°æ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÇ·á ¼ºñ½º Á¦°øÀÚ´Â Àû½Ã¿¡ Áø´Ü ¹× °³ÀÔÀ» À§ÇØ ÀÌ µµ±¸¿¡ Á¡Á¡ ´õ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ¹Ì±¹ ¼ÒȱâÇÐȸ(2024)´Â ¾à 6,000-7,000¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ À§Àå(GI) ÁúȯÀ» ¾Î°í ÀÖ´Ù°í º¸°íÇϰí ÀÖ½À´Ï´Ù. ¿°Áõ¼º ÀåÁúȯ(IBD), ±Ë¾ç¼º ´ëÀå¿°, Á÷Àå¿°, °Ô½ÇÁõ, ´ëÀå ¿ëÁ¾ µîÀÇ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â S»ó °áÀå°æÀÇ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ÀϹÝÀûÀ¸·Î ÇϺΠ¼ÒȰü, ƯÈ÷ Á÷Àå°ú SÀÚ °áÀå ºÎÀ§¿¡ ¿µÇâÀ» ¹ÌÄ¡¸ç S»ó °áÀå°æÀ» ÅëÇØ °¡Àå Àß º¼ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ´Â Á¡¸·ÀÇ ¿°ÁõÀ» ¸ð´ÏÅ͸µÇϰí Ä¡·á È¿°ú¸¦ Æò°¡Çϱâ À§ÇØ Á¤±âÀûÀÎ S»ó °áÀå°æ °Ë»ç°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù.
¶ÇÇÑ Johnson & Johnson Services, Inc., Olympus Corporation, Baxter¿Í °°Àº ÁÖ¿ä ±â¾÷ÀÇ ÅºÅºÇÑ À¯Åë¸ÁÀ» ¹è°æÀ¸·Î S»ó °áÀå°æÀºÀÌ Áö¿ª¿¡¼ ³Î¸® »ç¿ëµÇ°í ½±°Ô ±¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯¸®ÇÑ »óȯ Á¤Ã¥Àº äÅÃÀ» ´õ¿í ÃËÁøÇÏ¿© Å« ½ÃÀå ¼ºÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
°á·ÐÀûÀ¸·Î, ´ëÀå¾Ï ¹× ¼Òȱâ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ±â¼úÀû Á¢±Ù¼º, °·ÂÇÑ ½ÃÀå ÁøÀÔ ±â¾÷ ¹× Áö¿øÀûÀÎ ÀÇ·á Á¤Ã¥°ú °áÇÕÇÏ¿© ºÏ¹Ì S»ó °áÀå°æ ½ÃÀåÀÇ »ó´çÇÑ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
S»ó °áÀå°æ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷
S»ó °áÀå°æ ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ½ÃÀå Âü¿©Àڷδ Olympus Corporation, Baxter, Adler Instrument Company, Bioseal Inc., Rocket Medical plc., ConMed Corporation, Johnson &Johnson Services, Inc., Medtronic, Ambu A/S, SCHOLLY FIBEROPTIC GMBH, SonoScape Medical Corp., Interscope, Inc., Ovesco Endoscopy AG µîÀÌ ÀÖ½À´Ï´Ù.
S»ó °áÀå°æ ½ÃÀåÀÇ ÃÖ±Ù °³¹ß Ȱµ¿:
S»ó °áÀå°æ ½ÃÀå Á¶»ç º¸°í¼ÀÇ ÁÖ¿ä ¿äÁ¡
S»ó °áÀå°æ ½ÃÀå ÀÚÁÖ ¹¯´Â Áú¹®
Sigmoidoscopes Market by Product Type (Rigid and Flexible), Usability (Disposable and Reusable), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2032 owing to the increasing instances of chronic conditions and rising awareness about early diagnosis of gastro-intestinal disorders globally.
The sigmoidoscopes market is estimated to grow at a CAGR of 5.57% during the forecast period from 2025 to 2032. The sigmoidoscopes market is growing significantly due to the increasing instances of chronic conditions such colorectal cancer, inflammatory bowel diseases (IBD), diverticulitis, and polyps, growing geriatric population, rising awareness about early diagnosis of gastro-intestinal disorders, increasing shift towards minimally invasive procedures, and others that are expected to escalate the demand for sigmoidoscopes during the forecast period from 2025 to 2032.
Sigmoidoscopes Market Dynamics:
According to the Global Cancer Observatory (2024), colorectal cancer accounted for 50.2% of cancer cases in Asia, 27.9% in Europe, and 3.7% in Africa. The same source also reported that in 2022, there were approximately 1.39 million cases of colorectal cancer worldwide, a number projected to reach 3.29 million by 2045. This rising global burden is significantly driving the demand for sigmoidoscopes, as the need for early detection and diagnosis continues to grow.
Sigmoidoscopy plays a critical role in the early identification of colorectal cancer. It allows physicians to directly visualize the rectum and sigmoid colon, which are common sites for cancer and polyps. As a result, sigmoidoscopes are increasingly becoming a key component of preventive healthcare and routine diagnostic protocols.
In addition, the World Gastroenterology Organization (2024) reported that 49% of females and 36.6% of males met the criteria for at least one functional gastrointestinal disorder (FGID). The most prevalent disorders included functional constipation (11.7%), functional dyspepsia (7.2%), proctalgia fugax (5.9%), functional diarrhea (4.7%), and irritable bowel syndrome (IBS) (4.1%). Since many of these conditions require direct examination of the rectum and sigmoid colon for accurate diagnosis and treatment planning, the adoption of sigmoidoscopy procedures has surged across hospitals, clinics, and gastroenterology centers.
Furthermore, with the expected rise in global cancer incidence, healthcare systems are increasingly investing in advanced diagnostic tools and technologies. A greater emphasis is being placed on early detection and preventive care. For instance, in January 2024, Olympus Corporation acquired Taewoong Medical Co., Ltd. for USD 370 million. This strategic acquisition is aimed at expanding Olympus's gastrointestinal endotherapy portfolio and strengthening its capabilities in both diagnostic and therapeutic devices for GI disorders.
Moreover, according to the World Health Organization (2024), by 2050, around 80% of the global elderly population will reside in low- and middle-income countries. As older adults are more prone to gastrointestinal issues that require early diagnosis, the demand for accessible diagnostic solutions such as sigmoidoscopes is expected to increase significantly, especially in emerging markets.
Therefore, the combination of rising colorectal cancer prevalence, increasing incidence of FGIDs, growing geriatric population, and healthcare advancements is anticipated to drive robust growth in the sigmoidoscope market during the forecast period from 2025 to 2032.
However, the market may face certain limitations due to the availability of alternative diagnostic methods, potential risks of complications and infections associated with sigmoidoscopy, and patient discomfort, which could hinder its widespread adoption.
Sigmoidoscopes Market Segment Analysis:
Sigmoidoscopes Market by Product Type (Rigid and Flexible), Usability (Disposable and Reusable), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of sigmoidoscopes, the flexible category is expected to have a significant revenue share in the year 2024. This is due to the numerous advantages over rigid models. The growing adoption of flexible sigmoidoscopes is significantly boosting the overall market for sigmoidoscopes, largely due to their enhanced clinical utility, patient comfort, and evolving technology. Unlike rigid sigmoidoscopes, flexible variants allow for deeper navigation of the sigmoid colon and better maneuverability, enabling physicians to detect abnormalities with greater accuracy.
Additionally, these devices are less painful, often do not require sedation, and allow for procedures to be performed in outpatient settings, making them more accessible and cost-effective. For instance, Olympus Corporation, a global leader in endoscopy, offers advanced flexible sigmoidoscopes that are part of its EVIS EXERA III platform, known for high-definition imaging and Narrow Band Imaging (NBI) technology that enhances mucosal visualization. This allows for improved detection of colorectal polyps and early-stage cancer lesions. Another notable example is Pentax Medical, which manufactures flexible video sigmoidoscopes such as the EC-3490LK, featuring ergonomic design and HD+ visualization, widely used in GI units and clinics. These innovations have made flexible sigmoidoscopy more appealing for routine colorectal screenings, especially as health systems emphasize preventive care for colorectal cancer.
Additionally, companies like Ambu A/S have introduced single-use flexible sigmoidoscopes, such as the Ambu(R) aScope Gastro, addressing infection control concerns while offering convenience and sterility. The integration of flexible sigmoidoscopy into national cancer screening programs such as the NHS Bowel Scope Screening in the UK has further accelerated its clinical adoption. Overall, the increasing reliance on flexible sigmoidoscopes, combined with improvements in optical clarity, digital imaging, and single-use formats, is playing a pivotal role in driving the growth of the sigmoidoscope market globally.
North America is expected to dominate the overall sigmoidoscopes market:
Among all the regions, North America is expected to dominate the sigmoidoscopes market in the year 2024. This can be attributed to several factors, such as rising colorectal cancer cases, enhanced by technological advancements, regulatory approvals, and significant market presence of leading companies, continued investment in healthcare infrastructure, and innovative product developments that are expected to drive the market for sigmoidoscopes during the forecast period from 2025 to 2032.
According to data from the International Agency for Research on Cancer (2024), the number of new colorectal cancer cases in North America was approximately 184,000, and this figure is projected to rise to 250,000 by 2050. As the incidence of colorectal cancer continues to increase, the need for early detection and effective screening methods becomes more critical. Sigmoidoscopy, a key diagnostic procedure for examining the rectum and sigmoid colon, plays a vital role in identifying and monitoring colorectal abnormalities. With the rising burden of colorectal cancer, the demand for sigmoidoscopes is growing, as healthcare providers increasingly rely on this tool for timely diagnosis and intervention.
Additionally, the American Gastroenterological Association (2024) reported that approximately 60-70 million Americans are affected by gastrointestinal (GI) diseases. The increasing prevalence of conditions such as inflammatory bowel disease (IBD), ulcerative colitis, proctitis, diverticulosis, and colorectal polyps is further driving the demand for sigmoidoscopes. These disorders commonly affect the lower gastrointestinal tract, specifically the rectum and sigmoid colon areas, best visualized using a sigmoidoscope. For instance, patients with ulcerative colitis often require regular sigmoidoscopic evaluations to monitor mucosal inflammation and assess treatment response.
Moreover, the presence of key industry players such as Johnson & Johnson Services, Inc., Olympus Corporation, and Baxter, backed by robust distribution networks, ensures wide accessibility and availability of sigmoidoscopes across the region. In addition, favorable reimbursement policies further support adoption, creating significant market growth opportunities.
In conclusion, the rising prevalence of colorectal cancer and GI diseases, combined with technological accessibility, strong market players, and supportive healthcare policies, are expected to foster substantial growth for the sigmoidoscope market in North America.
Sigmoidoscopes Market Key Players:
Some of the key market players operating in the sigmoidoscopes market include Olympus Corporation, Baxter, Adler Instrument Company, Bioseal Inc., Rocket Medical plc., ConMed Corporation, Johnson & Johnson Services, Inc., Medtronic, Ambu A/S, SCHOLLY FIBEROPTIC GMBH, SonoScape Medical Corp., Interscope, Inc., Ovesco Endoscopy AG, and others.
Recent Developmental Activities in the Sigmoidoscopes Market:
Key takeaways from the sigmoidoscopes market report study
Target audience who can benefit from this sigmoidoscope market report study
Frequently Asked Questions for the Sigmoidoscopes Market: